FLAGSHIP PIONEERING TO HOST WEBINAR ON NEW APPROACH TO TACKLING PARKINSON'S DISEASE, ALZHEIMER'S, DIABETES AND OTHER COMMON ILLNESSES

USA Today's Karen Weintraub Will Moderate a Conversation with Doug Cole, MD, Flagship Managing Partner, and Christopher Austin, MD, Flagship CEO-Partner

News provided by

Flagship Pioneering

Feb 14, 2022, 10:44 ET

CAMBRIDGE, Mass., Feb. 14, 2022 /PRNewswire/ --

WHAT: Flagship Pioneering will host a virtual conversation on new approaches to Tackling Common Illnesses, such as diabetes, Alzheimer's, and Parkinson's Disease, which have few and/or insufficient treatment options. Register here: https://events.bizzabo.com/385385

WHY: Today, patients who share a diagnosis (e.g., diabetes) are in fact, not all suffering from the same underlying diseases, but often multiple different diseases, each affecting distinct groups of patients with distinct biological causes. This virtual conversation will address the critical need to fundamentally realign the way we diagnose and treat the underlying diseases that cause 90% of suffering and death in the world.

WHO: Karen Weintraub of USA Today will moderate a conversation with Doug Cole, Flagship Pioneering Managing Partner, and Christopher Austin, Flagship Pioneering CEO-Partner, on new approaches to tackling common illness.

WHEN: Tuesday, February 15, 2022, from Noon-1:00 PM Eastern

REGISTER: https://events.bizzabo.com/385385

About Flagship Pioneering

Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $140 billion in aggregate value. To date, Flagship has deployed over $2.6 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 42 transformative companies, including Axcella Health (Nasdaq: AXLA), Codiak BioSciences (Nasdaq: CDAK) Denali Therapeutics (Nasdaq: DNLI), Evelo Biosciences (Nasdaq: EVLO), Foghorn Therapeutics (Nasdaq: FHTX), Indigo Ag, Kaleido Biosciences (Nasdaq: KLDO), Moderna (Nasdaq: MRNA), Omega Therapeutics (Nasdaq: OMGA), Rubius Therapeutics (Nasdaq: RUBY), Sana Biotechnology (Nasdaq: SANA), Seres Therapeutics (Nasdaq: MCRB), and Sigilon Therapeutics (Nasdaq: SGTX).